Nasonex, Flonase Detail Aids Make Unproven Superiority Claims - DDMAC Letter
This article was originally published in The Pink Sheet Daily
FDA asks Schering-Plough, GlaxoSmithKline to pull detail material containing “unsubstantiated,” and “false and misleading” claims.
You may also be interested in...
Flonase follow-on is indicated for treatment of seasonal and perennial allergic rhinitis in adults and children two years of age and older.
Par and Roxane resume shipment of generic fluticasone following the expiration of a temporary restraining order.
Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee